EP Patent

EP3666750A1 — Crystalline form of bempedoic acid

Assigned to Sandoz AG · Expires 2020-06-17 · 6y expired

What this patent protects

The present invention concerns crystalline bempedoic acid, a process for obtaining crystalline bempedoic acid, and pharmaceutical compositions comprising crystalline bempedoic acid.

USPTO Abstract

The present invention concerns crystalline bempedoic acid, a process for obtaining crystalline bempedoic acid, and pharmaceutical compositions comprising crystalline bempedoic acid.

Drugs covered by this patent

Nexletol (BEMPEDOIC ACID) · Esperion Theraps Inc

Patent Metadata

Patent number: EP3666750A1
Jurisdiction: EP
Classification: —
Expires: 2020-06-17
Drug substance claim: No
Drug product claim: No
Assignee: Sandoz AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.